Lyra Therapeutics, Inc. (NASDAQ: LYRA) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
Lyra Therapeutics, Inc. (NASDAQ: LYRA) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating.
Lyra Therapeutics, Inc. (NASDAQ: LYRA) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $0.50 price target on the stock, down previously from $10.00.
Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]